CN103502247B - 7-氮杂吲哚衍生物 - Google Patents

7-氮杂吲哚衍生物 Download PDF

Info

Publication number
CN103502247B
CN103502247B CN201280007145.3A CN201280007145A CN103502247B CN 103502247 B CN103502247 B CN 103502247B CN 201280007145 A CN201280007145 A CN 201280007145A CN 103502247 B CN103502247 B CN 103502247B
Authority
CN
China
Prior art keywords
compound
pyrrolo
pyridin
mixture
proportions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280007145.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103502247A (zh
Inventor
D.多尔施
C.斯伦伯格
T.J.J.米勒
E.梅库
G.卡拉佩特延
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to CN201610048667.8A priority Critical patent/CN105732617B/zh
Priority to CN201610048764.7A priority patent/CN105712991B/zh
Publication of CN103502247A publication Critical patent/CN103502247A/zh
Application granted granted Critical
Publication of CN103502247B publication Critical patent/CN103502247B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201280007145.3A 2011-02-01 2012-01-09 7-氮杂吲哚衍生物 Expired - Fee Related CN103502247B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201610048667.8A CN105732617B (zh) 2011-02-01 2012-01-09 7‑氮杂吲哚衍生物
CN201610048764.7A CN105712991B (zh) 2011-02-01 2012-01-09 7‑氮杂吲哚衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011009961A DE102011009961A1 (de) 2011-02-01 2011-02-01 7-Azaindolderivate
DE102011009961.1 2011-02-01
PCT/EP2012/000067 WO2012104007A2 (de) 2011-02-01 2012-01-09 7-azaindolderivate

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201610048667.8A Division CN105732617B (zh) 2011-02-01 2012-01-09 7‑氮杂吲哚衍生物
CN201610048764.7A Division CN105712991B (zh) 2011-02-01 2012-01-09 7‑氮杂吲哚衍生物

Publications (2)

Publication Number Publication Date
CN103502247A CN103502247A (zh) 2014-01-08
CN103502247B true CN103502247B (zh) 2016-02-24

Family

ID=45554609

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201280007145.3A Expired - Fee Related CN103502247B (zh) 2011-02-01 2012-01-09 7-氮杂吲哚衍生物
CN201610048764.7A Expired - Fee Related CN105712991B (zh) 2011-02-01 2012-01-09 7‑氮杂吲哚衍生物
CN201610048667.8A Expired - Fee Related CN105732617B (zh) 2011-02-01 2012-01-09 7‑氮杂吲哚衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201610048764.7A Expired - Fee Related CN105712991B (zh) 2011-02-01 2012-01-09 7‑氮杂吲哚衍生物
CN201610048667.8A Expired - Fee Related CN105732617B (zh) 2011-02-01 2012-01-09 7‑氮杂吲哚衍生物

Country Status (18)

Country Link
US (3) US8981101B2 (cg-RX-API-DMAC10.html)
EP (3) EP2670748B1 (cg-RX-API-DMAC10.html)
JP (1) JP5891249B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140014158A (cg-RX-API-DMAC10.html)
CN (3) CN103502247B (cg-RX-API-DMAC10.html)
AR (1) AR085110A1 (cg-RX-API-DMAC10.html)
AU (1) AU2012213775B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013019028A2 (cg-RX-API-DMAC10.html)
CA (2) CA2826051C (cg-RX-API-DMAC10.html)
DE (1) DE102011009961A1 (cg-RX-API-DMAC10.html)
EA (1) EA201300873A1 (cg-RX-API-DMAC10.html)
ES (3) ES2634643T3 (cg-RX-API-DMAC10.html)
HK (1) HK1226394A1 (cg-RX-API-DMAC10.html)
IL (1) IL227689A0 (cg-RX-API-DMAC10.html)
MX (1) MX2013008212A (cg-RX-API-DMAC10.html)
SG (1) SG192133A1 (cg-RX-API-DMAC10.html)
WO (1) WO2012104007A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201306542B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110461841B (zh) * 2017-06-19 2020-09-15 上海和誉生物医药科技有限公司 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5826261B2 (ja) * 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌に対する使用のためのキナーゼ阻害剤としての２，４−ジアリール置換［１，８］ナフチリジン
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
ES2606638T3 (es) * 2012-02-21 2017-03-24 Merck Patent Gmbh Derivados de furopiridina
DE102012019369A1 (de) 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
FR3001219A1 (fr) * 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN105073747B (zh) * 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
SG11201701724VA (en) 2014-09-26 2017-04-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CA2975271A1 (en) 2015-03-04 2016-09-09 Dana-Farber Cancer Institute, Inc. Salicylate inhibitors of melk and methods of use
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2016287335B2 (en) * 2015-06-29 2020-01-23 Merck Patent Gmbh TBK/IKKepsilon inhibitor compounds and uses thereof
BR112017002594A2 (pt) 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
CN105906608B (zh) * 2016-05-03 2018-10-19 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
EP3801503A4 (en) 2018-06-07 2021-12-08 Disarm Therapeutics, Inc. INHIBITORS OF SARM1
CA3102645A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
JP7478142B2 (ja) * 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
KR20200046680A (ko) * 2018-10-25 2020-05-07 한국과학기술원 Pdk1 저해제를 포함하는 역노화 유도용 조성물
CN121487921A (zh) * 2023-07-14 2026-02-06 拜西欧斯（北京）生物技术有限公司 异喹啉衍生物、包含其的药物组合物以及它们的用途

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006063167A1 (en) * 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
CN1938303A (zh) * 2004-03-30 2007-03-28 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
CN1950083A (zh) * 2004-03-31 2007-04-18 艾文蒂斯药品公司 新吡咯并(2,3－b)吡啶衍生物，它们的制备与它们作为激酶抑制剂的药物用途
JP2007099640A (ja) * 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
WO2007107221A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
WO2007149427A2 (en) * 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
WO2009054941A1 (en) * 2007-10-25 2009-04-30 Merck & Co., Inc. Therapeutic compounds
DE102008025751A1 (de) * 2008-05-29 2009-12-03 Merck Patent Gmbh 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
WO2010000364A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
WO2010020308A1 (de) * 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindolderivate
CN101679425A (zh) * 2007-06-21 2010-03-24 默克专利有限公司 6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途
WO2010051781A1 (en) * 2008-10-27 2010-05-14 Shanghai Genomics, Inc. Kinase inhibitors and their use as pharmaceutical agents
WO2010127754A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
WO2000071524A1 (en) 1999-05-19 2000-11-30 Smithkline Beecham Plc 2-nh-pyridones and pyrimidones as mrs inhibitors
AU2004289539C1 (en) * 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
WO2005123672A2 (en) * 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
BRPI0608659A2 (pt) 2005-04-06 2010-11-30 Astrazeneca Ab composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
NZ592968A (en) * 2006-01-17 2012-08-31 Vertex Pharma Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2
ES2431466T3 (es) 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
CA2673003A1 (en) 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
AU2008226844A1 (en) 2007-03-13 2008-09-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
RU2503676C2 (ru) * 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Пирролопиразиновые ингибиторы киназы
EP2576549A4 (en) * 2010-05-24 2013-12-18 Univ Rochester Bicyclic Heteroarylkinase Inhibitors and Methods of Use
JP5826261B2 (ja) * 2010-06-28 2015-12-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌に対する使用のためのキナーゼ阻害剤としての２，４−ジアリール置換［１，８］ナフチリジン
DE102010053347A1 (de) 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938303A (zh) * 2004-03-30 2007-03-28 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
CN1950083A (zh) * 2004-03-31 2007-04-18 艾文蒂斯药品公司 新吡咯并(2,3－b)吡啶衍生物，它们的制备与它们作为激酶抑制剂的药物用途
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006063167A1 (en) * 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
JP2007099640A (ja) * 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
WO2007107221A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
WO2007149427A2 (en) * 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
CN101679425A (zh) * 2007-06-21 2010-03-24 默克专利有限公司 6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途
WO2009054941A1 (en) * 2007-10-25 2009-04-30 Merck & Co., Inc. Therapeutic compounds
DE102008025751A1 (de) * 2008-05-29 2009-12-03 Merck Patent Gmbh 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
WO2010000364A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
WO2010020308A1 (de) * 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindolderivate
WO2010051781A1 (en) * 2008-10-27 2010-05-14 Shanghai Genomics, Inc. Kinase inhibitors and their use as pharmaceutical agents
WO2010127754A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110461841B (zh) * 2017-06-19 2020-09-15 上海和誉生物医药科技有限公司 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用

Also Published As

Publication number Publication date
EP2670748A2 (de) 2013-12-11
ES2608317T3 (es) 2017-04-07
US9266887B2 (en) 2016-02-23
EP2746281B1 (de) 2017-04-26
AU2012213775A1 (en) 2013-09-19
EP3133074A2 (de) 2017-02-22
HK1226394A1 (zh) 2017-09-29
EP2746281A2 (de) 2014-06-25
CA2826051C (en) 2020-08-18
CN105732617A (zh) 2016-07-06
ES2634643T3 (es) 2017-09-28
US8981101B2 (en) 2015-03-17
CN105732617B (zh) 2017-12-01
ES2861048T3 (es) 2021-10-05
JP5891249B2 (ja) 2016-03-22
SG192133A1 (en) 2013-08-30
IL227689A0 (en) 2013-11-25
US20130310391A1 (en) 2013-11-21
US9725446B2 (en) 2017-08-08
EP3133074B1 (de) 2020-12-09
EP3133074A3 (de) 2017-05-17
US20150152104A1 (en) 2015-06-04
ZA201306542B (en) 2014-05-28
AR085110A1 (es) 2013-09-11
AU2012213775B2 (en) 2016-11-10
BR112013019028A2 (pt) 2016-10-04
US20160130269A1 (en) 2016-05-12
DE102011009961A1 (de) 2012-08-02
CN103502247A (zh) 2014-01-08
CA3082435A1 (en) 2012-08-09
CN105712991B (zh) 2017-12-01
JP2014509313A (ja) 2014-04-17
WO2012104007A2 (de) 2012-08-09
EP2670748B1 (de) 2016-09-28
KR20140014158A (ko) 2014-02-05
MX2013008212A (es) 2013-08-26
EP2746281A3 (de) 2014-10-08
AU2012213775A8 (en) 2013-10-24
EA201300873A1 (ru) 2014-02-28
CN105712991A (zh) 2016-06-29
WO2012104007A3 (de) 2013-10-17
CA2826051A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
JP5891249B2 (ja) ７−アザインドール誘導体
JP5731481B2 (ja) ３−（１，２，３−トリアゾール−４−イル）ピロロ［２，３−ｂ］ピリジン誘導体
JP5891233B2 (ja) ７−（［１，２，３］トリアゾール−４−イル）−ピロロ［２，３−ｂ］ピラジン誘導体
CN101679425A (zh) 6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途
JP6074364B2 (ja) ５−（１，２，３−トリアゾール−４−イル）−７ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体
JP5718359B2 (ja) ピロロ［２，３−ｂ］ピラジン−７−イルピリミジン化合物
CN103764651B (zh) 适合治疗癌症疾病的7-氮杂吲哚衍生物
HK1226407A1 (en) 7-azaindole derivatives
HK1189220A (en) 7-azaindole derivatives
HK1169118A (en) 3-([1,2,3]triazol-4-yl)-pyrrolo[2,3-b]pyridine derivatives
HK1142332A (en) 6-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1189220

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1189220

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160224

Termination date: 20220109

CF01 Termination of patent right due to non-payment of annual fee